About Us
About Guard Therapeutics Vision, Business Model & Goal The Board Management
Research
Kidney disease Science Pipeline RMC-035 GTX Peptides
Investor Relations
Financial calender Financial reports Share information Corporate governance General meetings Rights Issue 2025
Newsroom
Press releases Event calender Analyses and presentations Subscribe
Contact
Swe
Search

Financial reports

Financial reports

Interim reports

2025

Interim report January-March 2025

2024

Year-end Report 2024
Interim report January-September 2024
Interim report January-June 2024
Interim report January-March 2024

Other financial reports are currently only available in Swedish.

Guard Therapeutics is a Swedish clinical-stage biotechnology company that identifies and develops new therapies for diseases with a large unmet medical need, focusing on different forms of kidney disease. The company’s candidate drugs are based on the endogenous protein alpha-1-microglobulin. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Mail Address

Guard Therapeutics AB
Box 5216
102 45 Stockholm, Sweden

Visiting Address

Guard Therapeutics
Nybrogatan 34, 2 tr
114 39 Stockholm, Sweden

Follow us

LinkedIn X

Telephone

+46 (0)8 670 65 51

E-mail

info@guardtherapeutics.com

Privacy Policy © Guard Therapeutics International AB 2025